LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 151

Search options

  1. Article: This is Jeopardy! A flexible coverage-based schedule model to address wellness for pathology training programs.

    Scapa, Jason V / Naini, Bita V / Pullarkat, Sheeja / Sullivan, Peggy S

    Academic pathology

    2023  Volume 10, Issue 3, Page(s) 100087

    Abstract: Scheduling rotations for a pathology training program involves balancing educational requirements, service coverage, and paid time off (PTO). Absences can affect training as residents cross-cover, managing multiple services at once. Other specialties ... ...

    Abstract Scheduling rotations for a pathology training program involves balancing educational requirements, service coverage, and paid time off (PTO). Absences can affect training as residents cross-cover, managing multiple services at once. Other specialties utilize a "Jeopardy" based system for covering absences. In this system, residents on outpatient services are "jeopardized" to cover inpatient services for trainee absences. Borrowing this concept, we created a schedule model with a "Jeopardy-Elective" (JE) rotation to support resident absences. Prior to 2018-19, our residency program consisted of a 12 month-long rotation schedule. We adopted a 13 four-week block rotation model system, adding four JE rotations per resident over the course of training. The JE resident covered services during trainee absences and spent the remaining rotation on elective. We then conducted a pre- and post-intervention survey of all residents who trained in both systems. Following the change in schedule model, our results showed a statistically significant increase in resident satisfaction with taking PTO (p = 0.0014), finding coverage (p = 0.0006), and taking a sick day (p = 0.03). The mean number of days covered by the JE resident was 8.5 ± 2.7 workdays (out of 20). PTO usage increased from 16 to 20 days/resident while mean number of sick days decreased from 1.7 to 1.3 days per resident. There was overwhelming support with 82% of residents wanting to retain the new system going forward. Through use of the JE rotation, our program improved service coverage issues and resident satisfaction, with the long-term goal of enhanced resident well-being and enriched resident learning experiences.
    Language English
    Publishing date 2023-07-14
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2819382-9
    ISSN 2374-2895
    ISSN 2374-2895
    DOI 10.1016/j.acpath.2023.100087
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: C-As Bond Formation Reactions for the Preparation of Organoarsenic(III) Compounds.

    Tay, Wee Shan / Pullarkat, Sumod A

    Chemistry, an Asian journal

    2020  Volume 15, Issue 16, Page(s) 2428–2436

    Abstract: ... reactivities independent from that of other relatively more well explored Group V cogeners. ...

    Abstract Potential widespread applications of organoarsenic chemistry have been limited by the inherent lack of safe and effective As-C bond formation reactions. Several alternative reagents and methods have been developed in the last few decades to address the hazards and drawbacks associated with traditional arsenic synthetic strategies. Herein, this minireview summarizes the advances made in nucleophilic, electrophilic, radical and metal-mediated As(III)-C bond formations while specifically highlighting the behavior of arsenic synthons with various well-established reagents (eg. Grignard reagents, organolithium compounds, organometallic reagents, radical initiators and Lewis/Brønsted bases). Avenues for asymmetric synthesis are also discussed, as are recent advances in organoarsenic chemistry suggesting that arsines exhibit novel reactivities independent from that of other relatively more well explored Group V cogeners.
    Language English
    Publishing date 2020-07-13
    Publishing country Germany
    Document type Journal Article ; Review
    ZDB-ID 2233006-9
    ISSN 1861-471X ; 1861-4728
    ISSN (online) 1861-471X
    ISSN 1861-4728
    DOI 10.1002/asia.202000606
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Report of four acute myeloid leukemia patients with sustained complete remission with less frequent administration of decitabine and venetoclax.

    Aribi, Ahmed / Salhotra, Amandeep / Ball, Brian / Stein, Anthony / Marcucci, Guido / Pullarkat, Vinod

    Leukemia & lymphoma

    2023  Volume 64, Issue 4, Page(s) 897–899

    MeSH term(s) Humans ; Decitabine/therapeutic use ; Azacitidine/therapeutic use ; Bridged Bicyclo Compounds, Heterocyclic/adverse effects ; Remission Induction ; Leukemia, Myeloid, Acute/diagnosis ; Leukemia, Myeloid, Acute/drug therapy ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
    Chemical Substances Decitabine (776B62CQ27) ; venetoclax (N54AIC43PW) ; Azacitidine (M801H13NRU) ; Bridged Bicyclo Compounds, Heterocyclic
    Language English
    Publishing date 2023-02-27
    Publishing country United States
    Document type Letter
    ZDB-ID 1042374-6
    ISSN 1029-2403 ; 1042-8194
    ISSN (online) 1029-2403
    ISSN 1042-8194
    DOI 10.1080/10428194.2023.2179361
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Will immunotherapy lead to a breakthrough in the treatment of older adults with ALL?

    Aldoss, Ibrahim / Advani, Anjali / Pullarkat, Vinod

    Best practice & research. Clinical haematology

    2021  Volume 34, Issue 4, Page(s) 101319

    Abstract: Historically, older adults with B-cell acute lymphoblastic leukemia (ALL) have done poorly with chemotherapy-based treatment. Therefore, new innovative approaches are urgently needed to improve outcomes for this population. CD19-targeted immunotherapies ... ...

    Abstract Historically, older adults with B-cell acute lymphoblastic leukemia (ALL) have done poorly with chemotherapy-based treatment. Therefore, new innovative approaches are urgently needed to improve outcomes for this population. CD19-targeted immunotherapies such as blinatumomab and chimeric antigen receptor (CAR) T cell therapy have produced remarkable responses in relapsed/refractory (r/r) B-cell ALL, including clearance of minimal residual disease (MRD). Available data support the efficacy and safety of blinatumomab in older adults with advanced B-cell ALL. Therefore, its application is being extended to frontline regimens for B-cell ALL, particularly in older adults. There are several studies actively examining the role of blinatumomab alone or in combination with attenuated dosing of conventional chemotherapy or novel agents in older adults with newly diagnosed ALL and early data are encouraging. While CD19-targeted CAR (CD19CAR) T cell therapy is active in children and young adults with r/r B-cell ALL, data supporting its efficacy and safety in older adults with ALL is scarce. Furthermore, the commercially FDA approved CD19CAR T cell therapy product for r/r ALL is restricted only to patients ≤25 years of age. Although there are concerns about older adults tolerating the expected toxicities associated with CAR T cell therapy, which may be life threatening, tailored approaches for prophylactic and pre-emptive interventions combined with utilization of safer CAR T cell platforms may improve tolerability and further extend the use of this promising treatment to older patients with ALL. In this review, we will discuss the progress in immunotherapies for older adults with B-cell ALL and their potential for transforming frontline therapy for newly diagnosed patients.
    MeSH term(s) Aged ; Antigens, CD19 ; Humans ; Immunotherapy ; Immunotherapy, Adoptive ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy ; Recurrence
    Chemical Substances Antigens, CD19
    Language English
    Publishing date 2021-10-22
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 2048027-1
    ISSN 1532-1924 ; 1521-6926
    ISSN (online) 1532-1924
    ISSN 1521-6926
    DOI 10.1016/j.beha.2021.101319
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Therapy-related acute lymphoblastic leukaemia in women with antecedent breast cancer.

    Pourhassan, Hoda / Zhang, Jianying / Tinajero, Jose / Pullarkat, Vinod / Agrawal, Vaibhav / Koller, Paul / Al Malki, Monzr / Aribi, Ahmed / Salhotra, Amandeep / Sandhu, Karamjeet / Ali, Haris / Stein, Anthony / Marcucci, Guido / Forman, Stephen / Aldoss, Ibrahim

    British journal of haematology

    2024  

    Abstract: Therapy-related acute lymphoblastic leukaemia (tr-ALL) is a disease entity attributed to previous exposure to chemotherapy and/or radiation for antecedent malignancy. There is observed female predominance for tr-ALL, likely due to high prevalence and ... ...

    Abstract Therapy-related acute lymphoblastic leukaemia (tr-ALL) is a disease entity attributed to previous exposure to chemotherapy and/or radiation for antecedent malignancy. There is observed female predominance for tr-ALL, likely due to high prevalence and excellent curable rate for non-metastatic breast cancer as well as the frequent use of carcinogenic agents as part of adjuvant therapy. Here, we reviewed 37 women with diagnosis of ALL following breast cancer treatment with focus on cytogenetic categorization. Philadelphia chromosome positivity (Ph+), KMT2A alterations and other cytogenetic change groups were observed in 32%, 22% and 46% of patients respectively. Median overall survival (OS) and relapse-free survival (RFS) were 19.4 and 12.9 months, overall while both OS and RFS were superior in tr-ALL with Ph+ disease compared to KMT2Ar and other cytogenetics respectively. Seventeen (45.9%) patients underwent consolidative allogeneic haematopoietic cell transplantation (alloHCT) in CR1 out of which 4 (24%) relapsed following transplant. Both OS and RFS were superior in the KMT2Ar cytogenetics group following alloHCT. Ph chromosome represents the largest genetic entity of tr-ALL following breast cancer therapy, and it may be associated with superior survival outcomes while KMT2Ar may be associated with poorer outcomes that can perhaps be mitigated by alloHSCT.
    Language English
    Publishing date 2024-03-31
    Publishing country England
    Document type Journal Article
    ZDB-ID 80077-6
    ISSN 1365-2141 ; 0007-1048
    ISSN (online) 1365-2141
    ISSN 0007-1048
    DOI 10.1111/bjh.19432
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib.

    Ngo, Dat / Tinajero, Jose / Li, Shanpeng / Palmer, Joycelynne / Pourhassan, Hoda / Aribi, Ahmed / Nakamura, Ryotaro / Stein, Anthony / Marcucci, Guido / Salhotra, Amandeep / Sandhu, Karamjeet / Pullarkat, Vinod / Ball, Brian / Koller, Paul

    Leukemia & lymphoma

    2024  Volume 65, Issue 3, Page(s) 372–377

    Abstract: Relapsed or refractory (R/R) acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3 (FLT3) mutations remains a difficult and hard to treat entity. Gilteritinib is a potent oral FLT-3 inhibitor that improves overall survival in R/R AML, but studies ... ...

    Abstract Relapsed or refractory (R/R) acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3 (FLT3) mutations remains a difficult and hard to treat entity. Gilteritinib is a potent oral FLT-3 inhibitor that improves overall survival in R/R AML, but studies are limited in combining gilteritinib with a hypomethylating agent and venetoclax treatment backbone (HMA-VEN-GILT). Here we report our experience with HMA-VEN-GILT for 22 R/R FLT3 AML patients. HMA-VEN-GILT yielded an ORR of 77.3% (17/22), CR 4.5% (1/22), CRi 13.6% (3/22), MLFS 59.1% (13/22). Median follow-up was 10.4 months with a relapse rate of 29.4% (5/17), median time to relapse of 69 days (range 35-298 days), 6-month overall survival of 84%, and median OS of 10.1 months. Additionally, 36.4% (8/22) of patients proceeded to hematopoietic stem cell transplant. In conclusion, HMA-VEN-GILT for the treatment of R/R FLT3 AML is feasible and can be used as a bridge to allogeneic transplantation.
    MeSH term(s) Humans ; fms-Like Tyrosine Kinase 3/genetics ; Leukemia, Myeloid, Acute/diagnosis ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/genetics ; Recurrence ; Aniline Compounds ; Pyrazines ; Sulfonamides ; Bridged Bicyclo Compounds, Heterocyclic
    Chemical Substances gilteritinib (66D92MGC8M) ; venetoclax (N54AIC43PW) ; fms-Like Tyrosine Kinase 3 (EC 2.7.10.1) ; Aniline Compounds ; Pyrazines ; Sulfonamides ; Bridged Bicyclo Compounds, Heterocyclic
    Language English
    Publishing date 2024-01-02
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1042374-6
    ISSN 1029-2403 ; 1042-8194
    ISSN (online) 1029-2403
    ISSN 1042-8194
    DOI 10.1080/10428194.2023.2292473
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Radiologic Features of Well-circumscribed Orbital Tumors With Histopathologic Correlation: A Multi-center Study.

    Roelofs, Kelsey A / Juniat, Valerie / O'Rouke, Michael / Ledbetter, Luke / Hubschman, Sasha / Hardy, Thomas / Lee, Jean / Baugh, Samuel / Pullarkat, Sheeja T / Selva, Dinesh / Goldberg, Robert A / Rootman, Daniel B

    Ophthalmic plastic and reconstructive surgery

    2024  

    Abstract: Purpose: To delineate specific imaging characteristics of solitary fibrous tumors, schwannomas, cavernous venous malformations, and well-circumscribed orbital lymphoma.: Methods: Patients undergoing excisional biopsy of solitary fibrous tumor, ... ...

    Abstract Purpose: To delineate specific imaging characteristics of solitary fibrous tumors, schwannomas, cavernous venous malformations, and well-circumscribed orbital lymphoma.
    Methods: Patients undergoing excisional biopsy of solitary fibrous tumor, schwannomas, cavernous venous malformations, or well-circumscribed orbital lymphoma with preoperative MRIs available for review were identified at 3 academic centers in the United States and Australia. An exploratory statistical analysis was performed to identify important radiologic features, which were subsequently included in a random forest model. Histopathologic correlates were evaluated in representative cases.
    Results: A total of 91 cases were included with a mean age of 52.9 ± 17.2 years. Nearly all solitary fibrous tumors were located in the anterior or mid orbit (87.5%) and they more commonly demonstrated intralesional heterogeneity on T2-weighted imaging (45.5%) (p < 0.01). Compared with the other tumors, schwannomas tended to be intraconal (66.7%) and were often in the mid or posterior orbit (83.4%) (p < 0.01). Cavernous venous malformations characteristically demonstrated progressive contrast enhancement (93.9%; p < 0.01). Most lesions in all 4 groups were hypointense on T1-weighted imaging (80%-100%; p = 0.14) and only well-circumscribed orbital lymphoma tended to also be hypointense on T2 (81.8%) (p < 0.01). Finally, cases of lymphoma had significantly lower apparent diffusion coefficient ratios (0.9 ± 0.2) (p < 0.001), while the other 3 groups were not significantly different from one another (cavernous venous malformations: 1.8 ± 0.4; schwannomas: 1.8 ± 0.5; and solitary fibrous tumor: 1.6 ± 0.6) (p = 0.739).
    Conclusions: Key features that aid in the differentiation of these 4 tumors from one another include T2 intensity and homogeneity, early contrast-enhancement pattern, and ADC ratio.
    Language English
    Publishing date 2024-01-12
    Publishing country United States
    Document type Journal Article
    ZDB-ID 632830-1
    ISSN 1537-2677 ; 0740-9303
    ISSN (online) 1537-2677
    ISSN 0740-9303
    DOI 10.1097/IOP.0000000000002584
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Investigation of soft and living matter using a micro-extensional rheometer.

    Dubey, Sushil / Veer, Sukh / Seshagiri Rao, R V / Kalelkar, Chirag / Pullarkat, Pramod A

    Journal of physics. Condensed matter : an Institute of Physics journal

    2020  Volume 33, Issue 8, Page(s) 84003

    Abstract: Rheological properties of a material often require to be probed under extensional deformation. Examples include fibrous materials such as spider-silk, high-molecular weight polymer melts, and the contractile response of living cells. Such materials have ... ...

    Abstract Rheological properties of a material often require to be probed under extensional deformation. Examples include fibrous materials such as spider-silk, high-molecular weight polymer melts, and the contractile response of living cells. Such materials have strong molecular-level anisotropies which are either inherent or are induced by an imposed extension. However, unlike shear rheology, which is well-established, techniques to perform extensional rheology are currently under development and setups are often custom-designed for the problem under study. In this article, we present a versatile device that can be used to conduct extensional deformation studies of samples at microscopic scales with simultaneous imaging. We discuss the operational features of this device and present a number of applications.
    Language English
    Publishing date 2020-11-10
    Publishing country England
    Document type Journal Article
    ZDB-ID 1472968-4
    ISSN 1361-648X ; 0953-8984
    ISSN (online) 1361-648X
    ISSN 0953-8984
    DOI 10.1088/1361-648X/abc943
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: High remission rates and transition to allogeneic transplant in older patients with newly diagnosed FLT-3 mutated acute myelogenous leukemia with midostaurin plus intensive chemotherapy.

    Tinajero, Jose / Ngo, Dat / Zhang, Jianying / Tsai, Ni-Chun / Aribi, Ahmed / Aldoss, Ibrahim / Agrawal, Vaibhav / Arslan, Shukaib / Amanam, Idoroenyi / Pourhassan, Hoda / Sandhu, Karamjeet / Al-Malki, Monzr / Pullarkat, Vinod / Becker, Pamela / Nakamura, Ryotaro / Stein, Anthony / Marcucci, Guido / Artz, Andrew / Koller, Paul /
    Salhotra, Amandeep

    Leukemia & lymphoma

    2024  , Page(s) 1–4

    Language English
    Publishing date 2024-04-18
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1042374-6
    ISSN 1029-2403 ; 1042-8194
    ISSN (online) 1029-2403
    ISSN 1042-8194
    DOI 10.1080/10428194.2024.2332506
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: The feasibility of additional CD19-targeted cellular therapy in relapsed/refractory B-ALL with re-emergence of CD19 antigen after prior CD19-negative relapse.

    Agrawal, Vaibhav / Salhotra, Amandeep / Song, Joo / Gu, Zhaohui / Stein, Anthony S / Marcucci, Guido / Forman, Stephen J / Pullarkat, Vinod / Aldoss, Ibrahim

    American journal of hematology

    2022  Volume 98, Issue 2, Page(s) E38–E40

    MeSH term(s) Humans ; Antigens, CD19 ; Feasibility Studies ; Neoplasm Recurrence, Local ; Receptors, Antigen, T-Cell ; Receptors, Chimeric Antigen ; Burkitt Lymphoma ; Immunotherapy, Adoptive
    Chemical Substances Antigens, CD19 ; Receptors, Antigen, T-Cell ; Receptors, Chimeric Antigen
    Language English
    Publishing date 2022-12-04
    Publishing country United States
    Document type Letter
    ZDB-ID 196767-8
    ISSN 1096-8652 ; 0361-8609
    ISSN (online) 1096-8652
    ISSN 0361-8609
    DOI 10.1002/ajh.26787
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top